FDA
-
-
-
-
-
-
-
After-Hours Movers 08/08: (PBYI) (EIDX) (ALRM) Higher; (VRAY) (AMRN) (UBER) (more...)
-
-
-
-
-
-
-
Eidos Therapeutics (EIDX) Begins Phase 3 Study of AG10 in ATTR-CM with Registrational 12-month Endpoint
-
-
-
-
-
-
-
Eidos Therapeutics (EIDX) Says FDA Granted Orphan Drug Designation to its Product Candidate, AG10, for Treatment of Transthyretin Amyloidosis
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

